GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » X4 Pharmaceuticals Inc (FRA:48Q) » Definitions » Deferred Policy Acquisition Costs

X4 Pharmaceuticals (FRA:48Q) Deferred Policy Acquisition Costs


View and export this data going back to 2020. Start your Free Trial

What is X4 Pharmaceuticals Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


X4 Pharmaceuticals (FRA:48Q) Business Description

Industry
Traded in Other Exchanges
Address
61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream.